The global AI Pharma market size was valued at US$ million in 2023. With growing demand in downstream market, the AI Pharma is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period.
The research report highlights the growth potential of the global AI Pharma market. AI Pharma are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of AI Pharma. 麻豆原创 players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the AI Pharma market.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on AI Pharma market reflects various aspects and provide valuable insights into the industry.
麻豆原创 Size and Growth: The research report provide an overview of the current size and growth of the AI Pharma market. It may include historical data, market segmentation by Type (e.g., Self-developed Oipeline, Contract Research Organization (CRO)), and regional breakdowns.
麻豆原创 Drivers and Challenges: The report can identify and analyse the factors driving the growth of the AI Pharma market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the AI Pharma market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the AI Pharma industry. This include advancements in AI Pharma technology, AI Pharma new entrants, AI Pharma new investment, and other innovations that are shaping the future of AI Pharma.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the AI Pharma market. It includes factors influencing customer ' purchasing decisions, preferences for AI Pharma product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the AI Pharma market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting AI Pharma market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the AI Pharma market.
麻豆原创 Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the AI Pharma industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the AI Pharma market.
麻豆原创 Segmentation:
AI Pharma market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Self-developed Oipeline
Contract Research Organization (CRO)
Other
Segmentation by application
Preclinical Stage (Optimization of Lead Compounds, etc.)
Clinical Trial Phase (Predicting Treatment Outcome, etc.)
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Recursion
Insilico Medicine
Exscientia
BenevolentAI
Atomwise
Roivant Sciences
厂肠丑谤枚诲颈苍驳别谤
Lantern Pharma
XtalPi
Landos Biopharma
Relay Therapeutics
Accutar Biotech
Deep Genomics
Oncocross
AI Therapeutics
BioMap
METiS Pharmaceuticals
NeoX Biotech
StoneWise
Deep Intelligent Pharma
Gigaceuticals
Chemical.AI
Artivila
Galixir
Xbiome
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global AI Pharma 麻豆原创 Size 2019-2030
2.1.2 AI Pharma 麻豆原创 Size CAGR by Region 2019 VS 2023 VS 2030
2.2 AI Pharma Segment by Type
2.2.1 Self-developed Oipeline
2.2.2 Contract Research Organization (CRO)
2.2.3 Other
2.3 AI Pharma 麻豆原创 Size by Type
2.3.1 AI Pharma 麻豆原创 Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global AI Pharma 麻豆原创 Size 麻豆原创 Share by Type (2019-2024)
2.4 AI Pharma Segment by Application
2.4.1 Preclinical Stage (Optimization of Lead Compounds, etc.)
2.4.2 Clinical Trial Phase (Predicting Treatment Outcome, etc.)
2.5 AI Pharma 麻豆原创 Size by Application
2.5.1 AI Pharma 麻豆原创 Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global AI Pharma 麻豆原创 Size 麻豆原创 Share by Application (2019-2024)
3 AI Pharma 麻豆原创 Size by Player
3.1 AI Pharma 麻豆原创 Size 麻豆原创 Share by Players
3.1.1 Global AI Pharma Revenue by Players (2019-2024)
3.1.2 Global AI Pharma Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global AI Pharma Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 AI Pharma by Regions
4.1 AI Pharma 麻豆原创 Size by Regions (2019-2024)
4.2 Americas AI Pharma 麻豆原创 Size Growth (2019-2024)
4.3 APAC AI Pharma 麻豆原创 Size Growth (2019-2024)
4.4 Europe AI Pharma 麻豆原创 Size Growth (2019-2024)
4.5 Middle East & Africa AI Pharma 麻豆原创 Size Growth (2019-2024)
5 Americas
5.1 Americas AI Pharma 麻豆原创 Size by Country (2019-2024)
5.2 Americas AI Pharma 麻豆原创 Size by Type (2019-2024)
5.3 Americas AI Pharma 麻豆原创 Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC AI Pharma 麻豆原创 Size by Region (2019-2024)
6.2 APAC AI Pharma 麻豆原创 Size by Type (2019-2024)
6.3 APAC AI Pharma 麻豆原创 Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe AI Pharma by Country (2019-2024)
7.2 Europe AI Pharma 麻豆原创 Size by Type (2019-2024)
7.3 Europe AI Pharma 麻豆原创 Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa AI Pharma by Region (2019-2024)
8.2 Middle East & Africa AI Pharma 麻豆原创 Size by Type (2019-2024)
8.3 Middle East & Africa AI Pharma 麻豆原创 Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global AI Pharma 麻豆原创 Forecast
10.1 Global AI Pharma Forecast by Regions (2025-2030)
10.1.1 Global AI Pharma Forecast by Regions (2025-2030)
10.1.2 Americas AI Pharma Forecast
10.1.3 APAC AI Pharma Forecast
10.1.4 Europe AI Pharma Forecast
10.1.5 Middle East & Africa AI Pharma Forecast
10.2 Americas AI Pharma Forecast by Country (2025-2030)
10.2.1 United States AI Pharma 麻豆原创 Forecast
10.2.2 Canada AI Pharma 麻豆原创 Forecast
10.2.3 Mexico AI Pharma 麻豆原创 Forecast
10.2.4 Brazil AI Pharma 麻豆原创 Forecast
10.3 APAC AI Pharma Forecast by Region (2025-2030)
10.3.1 China AI Pharma 麻豆原创 Forecast
10.3.2 Japan AI Pharma 麻豆原创 Forecast
10.3.3 Korea AI Pharma 麻豆原创 Forecast
10.3.4 Southeast Asia AI Pharma 麻豆原创 Forecast
10.3.5 India AI Pharma 麻豆原创 Forecast
10.3.6 Australia AI Pharma 麻豆原创 Forecast
10.4 Europe AI Pharma Forecast by Country (2025-2030)
10.4.1 Germany AI Pharma 麻豆原创 Forecast
10.4.2 France AI Pharma 麻豆原创 Forecast
10.4.3 UK AI Pharma 麻豆原创 Forecast
10.4.4 Italy AI Pharma 麻豆原创 Forecast
10.4.5 Russia AI Pharma 麻豆原创 Forecast
10.5 Middle East & Africa AI Pharma Forecast by Region (2025-2030)
10.5.1 Egypt AI Pharma 麻豆原创 Forecast
10.5.2 South Africa AI Pharma 麻豆原创 Forecast
10.5.3 Israel AI Pharma 麻豆原创 Forecast
10.5.4 Turkey AI Pharma 麻豆原创 Forecast
10.5.5 GCC Countries AI Pharma 麻豆原创 Forecast
10.6 Global AI Pharma Forecast by Type (2025-2030)
10.7 Global AI Pharma Forecast by Application (2025-2030)
11 Key Players Analysis
11.1 Recursion
11.1.1 Recursion Company Information
11.1.2 Recursion AI Pharma Product Offered
11.1.3 Recursion AI Pharma Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.1.4 Recursion Main Business Overview
11.1.5 Recursion Latest Developments
11.2 Insilico Medicine
11.2.1 Insilico Medicine Company Information
11.2.2 Insilico Medicine AI Pharma Product Offered
11.2.3 Insilico Medicine AI Pharma Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.2.4 Insilico Medicine Main Business Overview
11.2.5 Insilico Medicine Latest Developments
11.3 Exscientia
11.3.1 Exscientia Company Information
11.3.2 Exscientia AI Pharma Product Offered
11.3.3 Exscientia AI Pharma Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.3.4 Exscientia Main Business Overview
11.3.5 Exscientia Latest Developments
11.4 BenevolentAI
11.4.1 BenevolentAI Company Information
11.4.2 BenevolentAI AI Pharma Product Offered
11.4.3 BenevolentAI AI Pharma Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.4.4 BenevolentAI Main Business Overview
11.4.5 BenevolentAI Latest Developments
11.5 Atomwise
11.5.1 Atomwise Company Information
11.5.2 Atomwise AI Pharma Product Offered
11.5.3 Atomwise AI Pharma Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.5.4 Atomwise Main Business Overview
11.5.5 Atomwise Latest Developments
11.6 Roivant Sciences
11.6.1 Roivant Sciences Company Information
11.6.2 Roivant Sciences AI Pharma Product Offered
11.6.3 Roivant Sciences AI Pharma Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.6.4 Roivant Sciences Main Business Overview
11.6.5 Roivant Sciences Latest Developments
11.7 厂肠丑谤枚诲颈苍驳别谤
11.7.1 厂肠丑谤枚诲颈苍驳别谤 Company Information
11.7.2 厂肠丑谤枚诲颈苍驳别谤 AI Pharma Product Offered
11.7.3 厂肠丑谤枚诲颈苍驳别谤 AI Pharma Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.7.4 厂肠丑谤枚诲颈苍驳别谤 Main Business Overview
11.7.5 厂肠丑谤枚诲颈苍驳别谤 Latest Developments
11.8 Lantern Pharma
11.8.1 Lantern Pharma Company Information
11.8.2 Lantern Pharma AI Pharma Product Offered
11.8.3 Lantern Pharma AI Pharma Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.8.4 Lantern Pharma Main Business Overview
11.8.5 Lantern Pharma Latest Developments
11.9 XtalPi
11.9.1 XtalPi Company Information
11.9.2 XtalPi AI Pharma Product Offered
11.9.3 XtalPi AI Pharma Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.9.4 XtalPi Main Business Overview
11.9.5 XtalPi Latest Developments
11.10 Landos Biopharma
11.10.1 Landos Biopharma Company Information
11.10.2 Landos Biopharma AI Pharma Product Offered
11.10.3 Landos Biopharma AI Pharma Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.10.4 Landos Biopharma Main Business Overview
11.10.5 Landos Biopharma Latest Developments
11.11 Relay Therapeutics
11.11.1 Relay Therapeutics Company Information
11.11.2 Relay Therapeutics AI Pharma Product Offered
11.11.3 Relay Therapeutics AI Pharma Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.11.4 Relay Therapeutics Main Business Overview
11.11.5 Relay Therapeutics Latest Developments
11.12 Accutar Biotech
11.12.1 Accutar Biotech Company Information
11.12.2 Accutar Biotech AI Pharma Product Offered
11.12.3 Accutar Biotech AI Pharma Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.12.4 Accutar Biotech Main Business Overview
11.12.5 Accutar Biotech Latest Developments
11.13 Deep Genomics
11.13.1 Deep Genomics Company Information
11.13.2 Deep Genomics AI Pharma Product Offered
11.13.3 Deep Genomics AI Pharma Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.13.4 Deep Genomics Main Business Overview
11.13.5 Deep Genomics Latest Developments
11.14 Oncocross
11.14.1 Oncocross Company Information
11.14.2 Oncocross AI Pharma Product Offered
11.14.3 Oncocross AI Pharma Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.14.4 Oncocross Main Business Overview
11.14.5 Oncocross Latest Developments
11.15 AI Therapeutics
11.15.1 AI Therapeutics Company Information
11.15.2 AI Therapeutics AI Pharma Product Offered
11.15.3 AI Therapeutics AI Pharma Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.15.4 AI Therapeutics Main Business Overview
11.15.5 AI Therapeutics Latest Developments
11.16 BioMap
11.16.1 BioMap Company Information
11.16.2 BioMap AI Pharma Product Offered
11.16.3 BioMap AI Pharma Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.16.4 BioMap Main Business Overview
11.16.5 BioMap Latest Developments
11.17 METiS Pharmaceuticals
11.17.1 METiS Pharmaceuticals Company Information
11.17.2 METiS Pharmaceuticals AI Pharma Product Offered
11.17.3 METiS Pharmaceuticals AI Pharma Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.17.4 METiS Pharmaceuticals Main Business Overview
11.17.5 METiS Pharmaceuticals Latest Developments
11.18 NeoX Biotech
11.18.1 NeoX Biotech Company Information
11.18.2 NeoX Biotech AI Pharma Product Offered
11.18.3 NeoX Biotech AI Pharma Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.18.4 NeoX Biotech Main Business Overview
11.18.5 NeoX Biotech Latest Developments
11.19 StoneWise
11.19.1 StoneWise Company Information
11.19.2 StoneWise AI Pharma Product Offered
11.19.3 StoneWise AI Pharma Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.19.4 StoneWise Main Business Overview
11.19.5 StoneWise Latest Developments
11.20 Deep Intelligent Pharma
11.20.1 Deep Intelligent Pharma Company Information
11.20.2 Deep Intelligent Pharma AI Pharma Product Offered
11.20.3 Deep Intelligent Pharma AI Pharma Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.20.4 Deep Intelligent Pharma Main Business Overview
11.20.5 Deep Intelligent Pharma Latest Developments
11.21 Gigaceuticals
11.21.1 Gigaceuticals Company Information
11.21.2 Gigaceuticals AI Pharma Product Offered
11.21.3 Gigaceuticals AI Pharma Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.21.4 Gigaceuticals Main Business Overview
11.21.5 Gigaceuticals Latest Developments
11.22 Chemical.AI
11.22.1 Chemical.AI Company Information
11.22.2 Chemical.AI AI Pharma Product Offered
11.22.3 Chemical.AI AI Pharma Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.22.4 Chemical.AI Main Business Overview
11.22.5 Chemical.AI Latest Developments
11.23 Artivila
11.23.1 Artivila Company Information
11.23.2 Artivila AI Pharma Product Offered
11.23.3 Artivila AI Pharma Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.23.4 Artivila Main Business Overview
11.23.5 Artivila Latest Developments
11.24 Galixir
11.24.1 Galixir Company Information
11.24.2 Galixir AI Pharma Product Offered
11.24.3 Galixir AI Pharma Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.24.4 Galixir Main Business Overview
11.24.5 Galixir Latest Developments
11.25 Xbiome
11.25.1 Xbiome Company Information
11.25.2 Xbiome AI Pharma Product Offered
11.25.3 Xbiome AI Pharma Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
11.25.4 Xbiome Main Business Overview
11.25.5 Xbiome Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.